Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β

Cancer Research

Volumn 72, Issue 16, 2012, Pages 4119-4129

  Hardee, Matthew E ^a   Marciscano, Ariel E ^a   Medina Ramirez, Christina M ^a   Zagzag, David ^a   Narayana, Ashwatha ^a   Lonning, Scott M ^b   Barcellos Hoff, Mary Helen ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[3 (PYRIDIN 2 YL) 4 (4 QUINOYL)] (4) 1H PYRAZOLE; ANTINEOPLASTIC AGENT; CELL DNA; CHEMOKINE RECEPTOR CXCR4; HISTONE H2AX; HTS 466284; LY 364947; NEUTRALIZING ANTIBODY; NOTCH1 RECEPTOR; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL RENEWAL; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA DAMAGE; DRUG MECHANISM; FEMALE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RADIATION RESPONSE; RADIOSENSITIVITY; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, NEUTRALIZING; BRAIN NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DNA DAMAGE; DNA, NEOPLASM; FEMALE; GLIOBLASTOMA; HUMANS; MICE; MICE, INBRED C57BL; MINK; NEOPLASTIC STEM CELLS; NEURAL STEM CELLS; PYRAZOLES; PYRROLES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84865140762     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0546     Document Type: Article

References (54)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
2. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 2003;100:15178-83. (Pubitemid 37518036)
3. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-8. (Pubitemid 37187480)
4. Rosenblum ML, Gerosa M, Dougherty DV, Reese C, Barger GR, Davis RL, et al. Age-related chemosensitivity of stem cells from human malignant brain tumours. Lancet 1982;1:885-7. (Pubitemid 12140282)
5. Frosina G. DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol Cancer Res 2009;7:989-99.
6. Castellino RC, Durden DL. Mechanisms of disease: the PI3K-Akt-PTEN signaling node-an intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol 2007;3:682-93. (Pubitemid 350238060)
7. Hambardzumyan D, Squatrito M, Carbajal E, Holland EC. Glioma formation, cancer stem cells, and Akt signaling. Stem Cell Rev 2008;4:203-10.
8. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60. (Pubitemid 44949604)
9. Mannino M, Chalmers AJ. Radioresistance of glioma stem cells: intrinsic characteristic or property of the 'microenvironment-stem cell unit'? Mol Oncol 2011;5:374-86.
10. Jamal M, Rath BH, Williams ES, Camphausen K, Tofilon PJ. Micro-environmental regulation of glioblastoma radioresponse. Clin Cancer Res 2010;16:6049-59.
11. Barcellos-Hoff MH, Newcomb EW, Zagzag D, Narayana A. Therapeutic targets in malignant glioblastoma microenvironment. Semin Radiat Oncol 2009 19:163-70.
12. Jachimczak P, Hessdorfer B, Fabel-Schulte K, Wismeth C, Brysch W, Schlingensiepen KH, et al. Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int J Cancer 1996;65:332-7. (Pubitemid 26059987)
13. Hau P, Jachimczak P, Schlaier J, Bogdahn U. TGF-b2 signaling in high-grade gliomas. Curr Pharm Biotechnol 2011;12:2150-7.
14. Baritaki S, Chatzinikola AM, Vakis AF, Soulitzis N, Karabetsos DA, Neonakis I, et al. YY1 Over-expression in human brain gliomas and meningiomas correlates with TGF-beta1, IGF-1 and FGF-2 mRNA levels. Cancer Invest 2009;27:184-92.
15. Pera MF, Tam PP. Extrinsic regulation of pluripotent stem cells. Nature 2010;465:713-20.
16. Aigner L, Bogdahn U. TGF-beta in neural stem cells and in tumors of the central nervous system. Cell Tissue Res 2008;331:225-41. (Pubitemid 350265484)
17. Peñuelas S, Anido J, Prieto-Sánchez RM, Folch G, Barba I, Cuartas I, et al. TGF-[beta] increases glioma-initiatingcell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 2009;15:315-27.
18. Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 2009;5:504-14.
19. Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Folch G, Carmona MA, et al. TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 2010;18:655-68.
20. Barcellos-Hoff MH. Radiation-induced transforming growth factor βand subsequent extracellular matrix reorganization in murine mammary gland. Cancer Res 1993;53:3880-6. (Pubitemid 23267682)
21. Ehrhart EJ, Carroll A, Segarini P, Tsang ML-S, Barcellos-Hoff MH. Latent transforming growth factor-β activation in situ: quantitative and functional evidence following low dose irradiation. FASEB J 1997;11:991-1002. (Pubitemid 27425901)
22. Wang J, Zheng H, Sung C-C, Richter KK, Hauer-Jensen M. Cellular sources of transforming growth factor-β isoforms in early and chronic radiation enteropathy. Am J Pathol 1998;153:1531-40. (Pubitemid 28509910)
23. Barcellos-Hoff MH, Dix TA. Redox-mediated activation of latent transforming growth factor-β1. Molec Endocrin 1996;10:1077-83. (Pubitemid 26299216)
24. Jobling MF, Mott JD, Finnegan M, Erickson AC, Taylor SE, Ledbetter S, et al. Isoform specificity of redox-mediated TGF-β activation. Radiat Res 2006;166:839-48.
25. Kirshner J, Jobling MF, Pajares MJ, Ravani SA, Glick A, Lavin M, et al. Inhibition of TGFβ1 signaling attenuates ATM activity in response to genotoxic stress. Cancer Res 2006;66:10861-68.
26. Wiegman EM, Blaese MA, Loeffler H, Coppes RP, Rodemann HP. TGFbeta-1 dependent fast stimulation of ATM and p53 phosphorylation following exposure to ionizing radiation does not involve TGFbeta-receptor I signalling. Radiother Oncol 2007;83:289-95. (Pubitemid 46907986)
27. Kanamoto T, Hellman U, Heldin CH, Souchelnytskyi S. Functional proteomics of transforming growth factor-beta1-stimulated Mv1Lu epithelial cells: Rad51 as a target of TGFbeta1-dependent regulation of DNA repair. EMBO J 2002;21:1219-30. (Pubitemid 34206195)
28. Bouquet SF, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, et al. Transforming growth factor ®1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res 2011;17:6754-65.
29. Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, Rifkin DB. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Analyt Biochem 1994;216:276-84. (Pubitemid 24076008)
30. Brown PD, Wakefield LM, Levinson AD, Sporn MB. Physicochemical activation of recombinant latent transforming growth factor-beta's 1, 2, and 3. Growth Factors 1990;3:35-43. (Pubitemid 20265013)
31. Costes SV, Ponomarev A, Chen JL, Nguyen D, Cucinotta FA, Barcellos-Hoff MH. Image-based modeling reveals dynamic redistribution of DNA damage into nuclear sub-domains. PLoS Comput Biol 2007;3:e155.
32. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004;3:1011-22. (Pubitemid 39642364)
33. Akhurst RJ. Large- and small-molecule inhibitors of transforming growth factor-beta signaling. Curr Opin Investig Drugs 2006;7:513-21. (Pubitemid 43891029)
34. Neumaier T, Swenson J, Pham C, Polyzos A, Lo AT, Yang P, et al. Evidence for formation of DNA repair centers and dose-response nonlinearity in human cells. Proc Natl Acad Sci 2012;109:443-8.
35. Schulte A, Gunther HS, Phillips HS, Kemming D, Martens T, Kharbanda S, et al. A distinct subset of glioma cell lines with stem cell-like properties reflects the transcriptional phenotype of glioblastomas and overexpresses CXCR4 as therapeutic target. Glia 2011;59:590-602.
36. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010;28:5-16.
37. Hauer-Jensen M, Richter KK, Wang J, Abe E, Sung CC, Hardin JW. Changes in transforming growth factor beta1 gene expression and immunoreactivity levels during development of chronic radiation enteropathy. Radiat Res 1998;150:673-80. (Pubitemid 28533708)
38. Pen A, Moreno MJ, Durocher Y, Deb-Rinker P, Stanimirovic DB. Glioblastoma-secreted factors induce IGFBP7 and angiogenesis by modulating Smad-2-dependent TGF-beta signaling. Oncogene 2008;27:6834-44.
39. Wesolowska A, Kwiatkowska A, Slomnicki L, Dembinski M, Master A, Sliwa M, et al. Microglia-derived TGF-beta as an important regulator of glioblastoma invasion-an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor. Oncogene 2008;27:918-30. (Pubitemid 351225378)
40. Baumann F, Leukel P, Doerfelt A, Beier CP, Dettmer K, Oefner PJ, et al. Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2. Neuro Oncol 2009;11:368-80.
41. Zhang M, Herion TW, Timke C, Han N, Hauser K, Weber KJ, et al. Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761. Neoplasia 2011 13:537-49.
42. Mengxian Z, Kleber S, Roehrich M, Timke C, Han N, Tuettenberg J, et al. Blockade of TGF-beta signaling by the TGF{beta}R-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 2011;71:7155-67.
43. Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A, et al. Inhibition of TGF-β2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 2007;17:201-12. (Pubitemid 47124417)
44. Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, et al. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro-Oncol 2011;13:132-42.
45. Lampson LA. Monoclonal antibodies in neuro-oncology: getting past the blood-brain barrier. MAbs 2011;3:153-60.
46. Hulper P, Schulz-Schaeffer W, Dullin C, Hoffmann P, Harper J, Kurtzberg L, et al. Tumor localization of an anti-TGF-beta antibody and its effects on gliomas. Int J Oncol 2011;38:51-9.
47. Beal K, Abrey LE, Gutin PH. Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol 2011;6:2.
48. Narayana A, Kunnakkat SD, Medabalmi P, Golfinos J, Parker E, Knopp E, et al. Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. Int J Radiat Oncol Biol Phys 2012;82:77-82.
49. Zheng M, Morgan-Lappe SE, Yang J, Bockbrader KM, Pamarthy D, Thomas D, et al. Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. Cancer Res 2008;68:7570-8.
50. Golding SE, Rosenberg E, Valerie N, Hussaini I, Frigerio M, Cockcroft XF, et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther 2009;8:2894-902.
51. Golding SE, Rosenberg E, Adams BR, Wignarajah S, Beckta JM, O'Connor MJ, et al. Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control. Cell Cycle 2012;11:1167-73.
52. Kil WJ, Cerna D, Burgan WE, Beam K, Carter D, Steeg PS, et al. In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res 2008;14:931-8. (Pubitemid 351231178)
53. McCord AM, Jamal M, Williams ES, Camphausen K, Tofilon PJ. CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin Cancer Res 2009;15:5145-53.
54. Krause M, Yaromina A, Eicheler W, Koch U, Baumann M. Cancer stem cells: targets and potential biomarkers for radiotherapy. Clin Cancer Res 2011;17:7224-9.